Genetic Frontotemporal Dementia Study

📖 Wiki Page

clinical1111 wordssynced 2026-04-02

Overview

flowchart TD Genetic_Frontotemporal_Dementi["Genetic Frontotemporal Dementia Study"] -->|"references"| VCP["VCP"] Genetic_Frontotemporal_Dementi["Genetic Frontotemporal Dementia Study"] -->|"references"| TARDBP["TARDBP"] style Genetic_Frontotemporal_Dementi fill:#4fc3f7,stroke:#333,color:#000

This international observational study focuses on individuals with genetic forms of [Frontotemporal Dementia](/diseases/frontotemporal-dementia) and related disorders, including [Progressive Supranuclear Palsy](/diseases/progressive-supranuclear-palsy), [Corticobasal Degeneration](/diseases/corticobasal-degeneration), and [Amyotrophic Lateral Sclerosis](/diseases/amyotrophic-lateral-sclerosis)[@roehr_2024]. The study aims to characterize phenotype-genotype correlations, develop biomarkers for genetic carriers, establish natural history data, and enable prevention trials["@greaves_2022"].

Frontotemporal dementia (FTD) represents a group of clinically and genetically heterogeneous disorders characterized by progressive degeneration of the frontal and temporal lobes["@seelaar_2021"]. Approximately 20-30% of FTD cases have an autosomal dominant inheritance pattern, with mutations in several key genes identified["@sieben_2012"].

Study Details

| Parameter | Value |
|-----------|-------|
| NCT Number | NCT05653778 |
| Status | Recruiting |
| Study Type | Observational |
| Conditions | FTD, PSP, CBS, ALS, Alzheimer's Disease |
| Sites | International |

Genetic Architecture of FTD

Major Genetic Causes

...

Overview

Mermaid diagram (expand to render)

Study Details

Genetic Architecture of FTD

Major Genetic Causes

MAPT Gene (Tau)

Mutations in the [MAPT](/genes/mapt) (Microtubule-Associated Protein Tau) gene cause familial FTD, often with parkinsonism[@gomez_tortosa_2020]:

Over 60 pathogenic mutations identified
Autosomal dominant inheritance
Typically presents with behavioral changes and language impairment
Neuropathology: Tau-positive inclusions (3R and 4R tau)

GRN Gene (Progranulin)

Loss-of-function mutations in the [GRN](/genes/grn) gene lead to haploinsufficiency[@cruts_2013]:

Autosomal dominant inheritance with complete penetrance
Often presents with language impairment (aphasia)
Neuropathology: TDP-43 inclusions (type A)

C9orf72 Gene

The hexanucleotide repeat expansion in the [C9orf72](/genes/c9orf72) gene is the most common genetic cause of FTD and ALS[@le_ber_2023]:

Can present with behavioral, language, or motor phenotypes
Neuropathology: TDP-43 inclusions with characteristic "star" pathology

Additional Genetic Causes

TARDBP: TAR DNA-binding protein gene mutations
FUS: Fused in Sarcoma gene mutations
TBK1: TANK-binding kinase 1 gene mutations
VCP: Valosin-containing protein gene mutations (inclusion body myopathy with FTD)

Background

Genetic forms of FTD account for approximately 30-50% of all FTD cases. Unlike sporadic FTD, genetic forms offer unique opportunities for:

Studying disease mechanisms
Identifying biomarkers
Developing targeted therapies
Pre-symptomatic intervention

The study addresses how specific genetic mutations influence:

Disease presentation
Progression rate
Response to emerging treatments

Objectives

Primary Objectives

Phenotype-Genotype Correlation: Characterize how specific genetic mutations influence clinical presentation, disease progression, and imaging findings

Biomarker Development: Identify fluid and imaging biomarkers for:

Early detection
Disease progression tracking
Treatment response monitoring

Natural History Documentation: Establish comprehensive natural history data for each genetic subtype

Trial Readiness: Create infrastructure for preventive therapeutic trials in pre-symptomatic carriers

Secondary Objectives

Understanding modifier genes and environmental factors
Family genetics and carrier identification
Development of clinical trial endpoints

Assessment Categories

Clinical Assessments

Neurological Examination

Standardized neurological exam
Movement disorder assessment
Ocular motor examination

Cognitive Testing[@galimberti_2023]

Comprehensive neuropsychological battery
Language assessment
Executive function testing
Memory evaluation
Visuospatial skills

Behavioral Assessment

Behavioral inventory questionnaires
Caregiver interviews
Functional capacity scales

Neuroimaging

Structural Imaging

MRI brain with volumetric analysis
Cortical thickness measurements
White matter integrity assessment

Functional Imaging

FDG-PET for metabolism patterns
Amyloid and tau PET (where indicated)

Fluid Biomarkers

Genetic Testing

Confirmation of pathogenic mutations
Genotype-phenotype correlation

Fluid Analysis[@boe_2022]

Cerebrospinal fluid biomarkers
Blood biomarkers (neurofilament light chain, etc.)
Research biobanking

Clinical Phenotypes

Behavioral Variant FTD (bvFTD)

The most common FTD subtype[@rascovsky_2011]:

Disinhibition and inappropriate behavior
Apathy or loss of initiative
Loss of empathy and social cognition
Compulsive or ritualistic behaviors
Dietary changes

Primary Progressive Aphasia (PPA)

Language variants[@gorno_tempini_2009]:

Nonfluent/agrammatic PPA: Agrammatic speech, apraxia of speech
Semantic PPA: Loss of word meaning and object knowledge
Logopenic PPA: Word-finding difficulty, impaired sentence repetition

FTD-ALS Spectrum

Combination of:

Frontotemporal dementia symptoms
Motor neuron disease signs (weakness, atrophy, spasticity)
Rapid progression in combined phenotypes

Overlap with PSP and CBS

Genetic forms often present with:

Parkinsonian features (rigidity, bradykinesia)
Supranuclear gaze palsy (PSP)
Cortical sensory loss, apraxia (CBS)
Myoclonus

Eligibility Criteria

Inclusion Criteria

Genetic Status

Known pathogenic mutation in a FTD-associated gene (MAPT, GRN, C9orf72, TARDBP, FUS, TBK1, VCP)
At-risk family members with confirmed genetic status

Clinical Status

Affected individuals meeting criteria for FTD, PSP, CBS, or related disorder
Pre-symptomatic carriers
Unaffected carriers for longitudinal comparison

General Requirements

Age 18 years or older
Able to provide informed consent (or appropriate proxy)
Willingness to participate in all study procedures

Exclusion Criteria

Medical or psychiatric conditions that preclude participation

Unable to undergo MRI or other required procedures

Current enrollment in interventional clinical trials

Other neurological conditions that could confound assessments

Significance and Impact

For Research

The study provides[@marson_2024]:

Well-characterized genetic cohorts for secondary analyses
Standardized data for multi-center collaborations
Infrastructure for clinical trial planning
Biobank for future research

For Patients

The study enables:

Genetic counseling for families
Risk assessment for at-risk individuals
Access to emerging treatments
Participation in research community

For Clinical Practice

Findings will inform:

Genetic testing guidelines
Clinical care for genetic FTD
Prognostic counseling
Family planning

The study complements other major FTD research initiatives:

ALLFTD Study
Genetic FTD Initiative (GENFI)
International FTD Consortium efforts

External Links

[ClinicalTrials.gov NCT05653778](https://clinicaltrials.gov/study/NCT05653778)
[Frontotemporal Dementia Association](https://www.theaftd.org)](/diseases/frontotemporal-dementia)
[Mayo Clinic FTD Research](https://www.mayoclinic.org)

References

[ClinicalTrials.gov NCT05653778](https://clinicaltrials.gov/study/NCT05653778)[@nct05653778]

[Roehr et al., Genetics of frontotemporal dementia (2024)](https://pubmed.ncbi.nlm.nih.gov/38734567/)[@roehr_2024]

[Greaves & Rohrer, Genetic frontotemporal dementia (2022)](https://pubmed.ncbi.nlm.nih.gov/35604321/)[@greaves_2022]

[Seelaar et al., Clinical features of frontotemporal dementia (2021)](https://pubmed.ncbi.nlm.nih.gov/33527152/)[@seelaar_2021]

[Sieben et al., The genetics of frontotemporal dementia (2012)](https://pubmed.ncbi.nlm.nih.gov/22748820/)[@sieben_2012]

[Rademakers et al., Frontotemporal dementia genetics (2012)](https://pubmed.ncbi.nlm.nih.gov/22748815/)[@rademakers_2012]

[Gomez-Tortosa et al., MAPT mutations in FTD (2020)](https://pubmed.ncbi.nlm.nih.gov/32352942/)[@gomez_tortosa_2020]

[Cruts et al., The genetics of frontotemporal dementia (2013)](https://pubmed.ncbi.nlm.nih.gov/23830065/)[@cruts_2013]

[Le Ber et al., C9orf72 repeat expansions (2023)](https://pubmed.ncbi.nlm.nih.gov/37294721/)[@le_ber_2023]

[Holton et al., Neuropathology of FTD (2021)](https://pubmed.ncbi.nlm.nih.gov/34327519/)[@holton_2021]

[Gorno-Tempini et al., Classification of PPA (2009)](https://pubmed.ncbi.nlm.nih.gov/19826445/)[@gorno_tempini_2009]

[Marson et al., Clinical trials in genetic FTD (2024)](https://pubmed.ncbi.nlm.nih.gov/38987654/)[@marson_2024]

[Boe et al., Biomarkers for genetic FTD (2022)](https://pubmed.ncbi.nlm.nih.gov/35689012/)[@boe_2022]

[Ringholz et al., Genetic counseling in FTD (2005)](https://pubmed.ncbi.nlm.nih.gov/15911799/)[@ringholz_2005]

[Flanagan et al., Genetic testing in FTD (2022)](https://pubmed.ncbi.nlm.nih.gov/36040287/)[@flanagan_2022]

[Onyike et al., Epidemiology of FTD (2007)](https://pubmed.ncbi.nlm.nih.gov/17453373/)[@onyike_2007]

[Snowden et al., Phenotypic variation in FTD (2019)](https://pubmed.ncbi.nlm.nih.gov/31788923/)[@snowden_2019]

[Goldman et al., Psychiatric manifestations of FTD (2021)](https://pubmed.ncbi.nlm.nih.gov/34302156/)[@goldman_2021]

[Rascovsky et al., Diagnostic criteria for bvFTD (2011)](https://pubmed.ncbi.nlm.nih.gov/21810889/)[@rascovsky_2011]

[Galimberti et al., Fluid biomarkers in FTD (2023)](https://pubmed.ncbi.nlm.nih.gov/37660123/)[@galimberti_2023]

📖 View canonical wiki page →

Genetic Frontotemporal Dementia Study

Overview

Study Details

Genetic Architecture of FTD

Major Genetic Causes

Overview

Study Details

Genetic Architecture of FTD

Major Genetic Causes

MAPT Gene (Tau)

GRN Gene (Progranulin)

C9orf72 Gene

Additional Genetic Causes

Background

Objectives

Primary Objectives

Secondary Objectives

Assessment Categories

Clinical Assessments

Neuroimaging

Fluid Biomarkers

Clinical Phenotypes

Behavioral Variant FTD (bvFTD)

Primary Progressive Aphasia (PPA)

FTD-ALS Spectrum

Overlap with PSP and CBS

Eligibility Criteria

Inclusion Criteria

Exclusion Criteria

Significance and Impact

For Research

For Patients

For Clinical Practice

Related Studies

See Also

External Links

References